This activity was originally broadcast live as a satellite symposium held in conjunction with the 2022 AMCP Annual Meeting.
Program Description
When involved in the treatment and management of patients with non-small cell lung cancer (NSCLC), managed care pharmacists must consider how use of predictive biomarkers can affect patient response to therapy. Several organizations recommend use of biomarker testing before initiating treatment for patients with NSCLC, and managed care professionals can ensure these recommendations are incorporated into treatment protocols. Evidence for first-line treatment regimens with immune checkpoint inhibitors (ICIs) will be presented, as well as considerations for managing immune-mediated adverse effects of therapy. This activity will also explore strategies managed care pharmacists can take to minimize the financial burden associated with use of ICIs in patients with NSCLC.
Target Audience: Managed care pharmacists and oncology pharmacists
Type of Activity: Application
Release date: April 22, 2022
Expiration date: April 22, 2023
Time to complete activity: 1.5 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Determine the clinical and economic value of PD-L1 testing in patients with non-small cell lung cancer (NSCLC) who are being considered for frontline treatment with immune checkpoint inhibitors (ICIs).
- Examine available clinical data related to the frontline use of ICIs in the management of advanced NSCLC.
- Investigate the impact of ICIs on quality of life and resource utilization associated with frontline use of ICIs in advanced NSCLC.
Paul Forsberg, PharmD, MHA, BCOP
Director of Pharmacy
Minnesota Oncology
St. Paul, Minnesota
Latha Radhakrishnan, PharmD, BCOP
Clinical Oncology Pharmacist
The University of Illinois Hospital and Health Sciences System
Clinical Assistant Professor
University of Illinois at Chicago College of Pharmacy
Chicago, Illinois
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-196-H01-P. The activity is available for CE credit through April 22, 2023.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Paul Forsberg, PharmD, MHA, BCOP, has the following relevant financial relationships with commercial interests to disclose:
Consultant: Epizyme
Speakers Bureau: AstraZeneca
Latha Radhakrishnan, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:
Consultant: Taiho, Novartis, Exelixis
Speakers Bureau: BMS, AstraZeneca, Taiho, Exelixis
Pharmacy Times Continuing Education™ Planning Staff— Jim Palatine, RPh, MBA; Amy H. Seung, PharmD, BCOP, FHOPA; Dipti Desai, PharmD, CHCP; Liza Patel, PharmD, RPh; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with commercial interests to disclose.
Anonymous peer reviewers have been used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
The content of this activity may include information regarding the use of products that may be inconsistent with, or outside the approved labeling for, these products in the United States. Pharmacists should note that the use of these products outside current approved labeling is considered experimental and are advised to consult the prescribing information for these products.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms